MoleculeMind Achieves Breakthrough in AI-Powered Nanobody Design with MMDesign Platform
MoleculeMind, an AI protein design company founded by Professor Xu Jinbo — a pioneer in AI protein folding — has announced a major breakthrough with its self-developed MMDesign platform for AI-powered de novo biologics design, achieving over 90% target success rate in nanobody design across more than a dozen real-world targets with minimal experimental samples. Traditional antibody discovery relies heavily on animal immunization orlarge-scale library screening, often requirin
MoleculeMind has unveiled its MMDesign platform, an artificial intelligence system for designing novel nanobodies, a type of therapeutic antibody. The platform demonstrated a success rate exceeding 90% across more than a dozen diverse biological targets, requiring minimal experimental testing. This AI-driven approach significantly deviates from traditional, high-volume screening methods, which are often costly and inefficient.
MMDesign achieved remarkable results, including the design of highly potent nanobodies with affinities in the nanomolar and picomolar ranges. The platform successfully tackled challenging targets like TNF alpha and GPCRs, areas where previous low-throughput AI designs had faltered. This advancement promises to accelerate drug discovery timelines and reduce associated expenses.
This breakthrough could revolutionize antibody drug discovery by making it faster, cheaper, and more efficient, potentially leading to quicker development of new therapies.
📌 Kaynak
Bu özet Pandaily kaynağından otomatik derlenmiştir. Tamamı için orijinal habere gidin.
Orijinal haberi oku →